Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer

Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer - Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041621

Enrollment

239

Registered

2020-09-15

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All patients enrolled in clinical trials of trifluridine/tipiracil hydrochloride (FTD/TPI) plus bevacizumab conducted in Japan for which individual case data were available were included.

Exclusion criteria

Exclusion criteria: Nothing in particular

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events Response to treatment Disease control rate Objective response rate Overall survival Progression free survival Time to treatment failure	—

Countries

Japan

Contacts

Public ContactTakeshi Kawakami

Shizuoka Cancer Center Division of Gastrointestinal Oncology

t.kawakami@scchr.jp055-989-5222

Outcome results